Narrow search
Showing 1 - 10 of 6,842
Cover Image
Therapeutic substitution post-patent expiry : the cases of ACE inhibitors and proton pump inhibitors
Vandoros, Sotris - In: Health economics 23 (2014) 5, pp. 621-630
Persistent link: https://www.econbiz.de/10011305497
Cover Image
The tools of globalization : ways of regulating and the structure of the international regime for pharmaceuticals
Demortain, David - In: Review of international political economy : RIPE 22 (2015) 6, pp. 1249-1275
Persistent link: https://www.econbiz.de/10011453911
Cover Image
Umbrella branding in pharmaceutical markets
Suppliet, Moritz - 2017
Persistent link: https://www.econbiz.de/10011734578
Cover Image
The economic driven by politics as values : the example of pharmaceuticals in France
Smith, Andy - In: New political economy 22 (2017) 6, pp. 611-627
Persistent link: https://www.econbiz.de/10011742973
Cover Image
Chapter Twelve. Markets for Pharmaceutical Products
Scott Morton, Fiona; Kyle, Margaret - In: Handbook of health economics : volume 2, (pp. 763-823). 2011
This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is … also characterized by extensive regulation of almost every activity, from product development through manufacturing and …
Persistent link: https://www.econbiz.de/10014025576
Cover Image
Market power and regulation in pharmaceutical markets
Gugler, Klaus; Szücs, Florian - 2023
Persistent link: https://www.econbiz.de/10014321635
Cover Image
Bulk drug industry in India : challenges and prospects
James, T. C. - 2020
Persistent link: https://www.econbiz.de/10013466790
Cover Image
Parallel imports under a manufacturer rebate and a price freeze : evidence from Germany
Birg, Laura - In: Health economics 32 (2023) 2, pp. 302-323
Persistent link: https://www.econbiz.de/10014266802
Cover Image
Pharmaceutical regulation in Europe and its impact on corporate R&D
Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9
expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically … assessing the impact of regulation on pharmaceutical R&D expenditures. Methods: We analyze a sample of 20 leading pharmaceutical … companies between 2000 and 2008. The share of sales in Europe serves as a proxy for the degree of pharmaceutical regulation. We …
Persistent link: https://www.econbiz.de/10010526909